PROCEPT BioRobotics Corp. to Present at the 43rd Annual Cowen Health Care Conference in Boston

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) has announced that its management will present at the 43rd Annual Cowen Health Care Conference in Boston on March 7, 2023, at 12:50 p.m. Eastern Time. Interested parties can access a live webcast and an archived recording on the company’s website for at least 90 days following the event.

PROCEPT is recognized for its AquaBeam Robotic System, aimed at enhancing minimally invasive surgery for benign prostatic hyperplasia (BPH). Currently, BPH affects around 40 million men in the U.S., and PROCEPT's innovative Aquablation therapy is supported by extensive clinical evidence, including nine studies and over 100 peer-reviewed publications.

REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT^® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 43rd Annual Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 7 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com

FAQ

When will PROCEPT BioRobotics present at the Cowen Health Care Conference?

PROCEPT BioRobotics will present on March 7, 2023, at 12:50 p.m. Eastern Time.

How can I watch the PROCEPT BioRobotics presentation?

You can watch the live webcast and access an archive on PROCEPT's investors' webpage.

What is the AquaBeam Robotic System?

The AquaBeam Robotic System is designed for minimally invasive surgery, particularly for treating benign prostatic hyperplasia (BPH).

What is benign prostatic hyperplasia (BPH)?

BPH is the most common prostate disease, affecting around 40 million men in the United States.

What evidence supports Aquablation therapy?

Aquablation therapy is backed by nine clinical studies and over 100 peer-reviewed publications demonstrating its effectiveness.